Name | Value |
---|---|
Revenues | 5,029.0K |
Cost of Revenue | 876.0K |
Gross Profit | 4,153.0K |
Operating Expense | 6,101.0K |
Operating I/L | -1,948.0K |
Other Income/Expense | 217.0K |
Interest Income | 206.0K |
Pretax | -1,731.0K |
Income Tax Expense | 8.0K |
Net Income/Loss | -1,739.0K |
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for cancer treatment. The company's Cancer Detection segment offers AI algorithm solutions for mammography and breast cancer risk estimation, as well as MRI applications for breast and prostate cancer detection. Its Cancer Therapy segment provides electronic brachytherapy systems for early stage breast, non-melanoma skin, and gynecological cancers. iCAD sells its products through direct sales organizations, OEM partners, distributors, and resellers, and exports internationally. Its revenue is generated from the sales of imaging analysis platforms, AI algorithms, and radiation therapy systems.